Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR183 | P32249 | 6/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 3/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2299183 | 1.00 | GPR183 (0.41) | GPR183MEN1KMT2AACHENAMPT | |
| Hydrochloric Acid SCHEMBL13582551 | 0.99 | GPR183 (0.41) | GPR183MEN1KMT2AACHENAMPT | |
| Hydrochloric Acid SCHEMBL13582553 | 0.99 | GPR183 (0.41) | GPR183MEN1KMT2AACHENAMPT | |
| SCHEMBL13583069 | 0.95 | ACHE (0.42) | GPR183MEN1KMT2AACHENAMPT | |
| SCHEMBL13583067 | 0.95 | ACHE (0.42) | GPR183MEN1KMT2AACHENAMPT | |
| Hydrochloric Acid SCHEMBL13582760 | 0.95 | ACHE (0.42) | GPR183MEN1KMT2AACHENAMPT | |
| Hydrochloric Acid SCHEMBL13582764 | 0.95 | ACHE (0.42) | GPR183MEN1KMT2AACHENAMPT | |
| SCHEMBL13582299 | 0.94 | GPR183 (0.43) | GPR183MEN1KMT2AACHENAMPT | |
| SCHEMBL13582300 | 0.94 | GPR183 (0.43) | GPR183MEN1KMT2AACHENAMPT | |
| Hydrochloric Acid SCHEMBL2233283 | 0.93 | GPR183 (0.42) | GPR183MEN1KMT2AACHENAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528897-B9 | DI-SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMA CO LTD (JP) | 2015-04-22 | — | — | EP | claimed |
| EP-2528897-B1 | DI-SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMA CO LTD (JP) | 2014-10-15 | — | — | EP | claimed |
| US-8722663-B2 | Di-substituted pyridine derivatives as anticancers | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-05-13 | — | — | US | claimed |
| EP-2528897-A1 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2012-12-05 | — | — | EP | claimed |
| US-20120283242-A1 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-11-08 | — | — | US | claimed |
| WO-2011093524-A9 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-12-01 | — | — | WO | claimed |
| WO-2011093524-A1 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-08-04 | — | — | WO | claimed |
| US-9023914-B2 | Nitrile rubbers and production thereof in organic solvents | LANXESS DEUTSCHLAND GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| EP-2528897-B9 | DI-SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMA CO LTD (JP) | 2015-04-22 | — | — | EP | disclosed |
| EP-2528897-B1 | DI-SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMA CO LTD (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-8722663-B2 | Di-substituted pyridine derivatives as anticancers | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-05-13 | — | — | US | disclosed |
| EP-2528897-A1 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2012-12-05 | — | — | EP | disclosed |
| US-20120283351-A1 | NITRILE RUBBERS AND PRODUCTION THEREOF IN ORGANIC SOLVENTS | LANXESS DEUTSCHLAND GMBH (DE) | 2012-11-08 | — | — | US | disclosed |
| US-20120283242-A1 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-11-08 | — | — | US | disclosed |
| WO-2011093524-A1 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283242-A1 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | TPD52L2, CCNE2, CDK2 | GPR183 1249/4885MEN1 2854/4885KMT2A 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.